#16
|
|||
|
|||
Âñòðåòèë ìåòà-àíàëèç, îïóáëèêîâàííûé íåäàâíî â JAMA è âñïîìíèë ýòó òåìó.
Öèòàòà:
|
#17
|
||||
|
||||
Öèòàòà:
|
#18
|
||||
|
||||
Ïåðåâîæó áðèòàíñêèé ÷åðíîâèê ãàéäà ïî îñòàíîâêå ñåðäöà (2008) è ñåé÷àñ íàáðåë:
1.8 Patients admitted to ICU after cardiac arrest should have their blood glucose monitored frequently and hyperglycaemia treated with an insulin infusion. Recent studies indicate that post cardiac arrest patients may be treated optimally with a target range for blood glucose concentration of up to 8 mmol l-1. |
#19
|
|||
|
|||
À ó Âàñ, Àëåêñàíäð, êàêèå öåëåâûå çíà÷åíèÿ ãëèêåìèè ÿâëÿþòñÿ îðèåíòèðîì ?
|
#20
|
||||
|
||||
Íà èíôóçîìàòå - îêîëî 10 ììîëü/ë ñòðåìèìñÿ äîñòè÷ü. Ïîòîì íà ïîäêîæíûå ïåðåõîäèì.
|
#21
|
||||
|
||||
Ìíå âñåãäà ýòîò ìîìåíò áûë èíòåðåñåí. Ó ÷åëîâåêà, êîòîðûé íå åñò, âðîäå áû ñîâñåì íè ê ÷åìó ïåðåõîäèòü íà ïîäêîæíîå ââåäåíèå êîðîòêîãî. "Ãîðêè" óñòðàèâàòü..
__________________
Àííà, âðà÷-ýíäîêðèíîëîã Âîðîíåæ, êëèíèêà Íåïëàöåáî |
#22
|
|||
|
|||
Ñòðåìèìñÿ áûòü â èíòåðâàëå 6-8 (åñëè ðóêè ó ñåñòåð ïðÿìûå - ïî÷òè âñåãäà óäàåòñÿ), ïîêà åñòü íå íà÷íåò - íèêàêîãî ï/ê èíñóëèíà.
|
|
#23
|
||||
|
||||
Êîëëåãè, ìîæåò áûòü, êîìó-òî áóäåò èíòåðåñíà ñòàòüÿ ïî ìîòèâàì DIGAMI-1 è DIGAMI-2 (õîòÿ îíà è íà ðóññêîì - íå ïåðâîèñòî÷íèê )
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Îïóáëèêîâàíà â æóðíàëå "Ñàõàðíûé äèàáåò", 2008, êàæåòñÿ, ¹1. |
#24
|
||||
|
||||
|
#25
|
||||
|
||||
Àõ, îí åñò! Âîò ïîýòîìó è äèàáåò ó íåãî
__________________
Àííà, âðà÷-ýíäîêðèíîëîã Âîðîíåæ, êëèíèêà Íåïëàöåáî |
#26
|
||||
|
||||
Intensive Glycemic Control and the Prevention of Cardiovascular Events:the Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. A Position Statement of the American Diabetes Association and a Scientific Statement of
American College of Cardiology Foundation and the American Heart Association [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#27
|
||||
|
||||
Öèòàòà:
Intånsivå Gluñîså Ñîntrîl Hàrms Ñritiñàlló Ill Pàtiånts Mîrå åvidånñå thàt just kååping gluñîså låvåls <180 mg/dL is båttår thàn striving fîr våró lîw låvåls. Priîr studiås îf thå åffåñts îf intånsivå gluñîså ñîntrîl in ñritiñàlló ill pàtiånts hàvå óiåldåd ñînfliñting råsults. Nîw, in à multiñåntår triàl (NIÑÅ-SUGÀR), invåstigàtîrs ràndîmizåd mîrå thàn 6000 ñritiñàlló ill pàtiånts (63% mådiñàl; 37% surgiñàl) tî åithår intånsivå gluñîså ñîntrîl (tàrgåt gluñîså låvål, 81–108 mg/dL) îr ñînvåntiînàl gluñîså ñîntrîl (tàrgåt gluñîså låvål, 144–180 mg/dL). Ñîntrîl îf blîîd gluñîså wàs àñhiåvåd with intràvånîus insulin infusiîns. Pàrtiñipànts wårå ràndîmizåd within 24 hîurs àftår àdmissiîn tî intånsivå ñàrå units ànd wårå åxpåñtåd tî råquirå IÑU tråàtmånt fîr 3 îr mîrå ñînsåñutivå dàós. Thå primàró åndpîint — dåàth bó 90 dàós àftår ràndîmizàtiîn — îññurråd signifiñàntló mîrå îftån in thå intånsivå-ñîntrîl grîup thàn in thå ñînvåntiînàl-ñîntrîl grîup (27.5% vs. 24.9%). Whån dàtà wårå ànàlózåd såpàràtåló fîr mådiñàl ànd surgiñàl pàtiånts, råsults wårå similàr tî thîså fîr thå whîlå ñîhîrt. Nît surprisingló, såvårå hópîglóñåmià (blîîd gluñîså låvål, <40 mg/dL) wàs signifiñàntló mîrå ñîmmîn in thå intånsivå-ñîntrîl grîup thàn in thå ñînvåntiînàl-ñîntrîl grîup (6.8% vs. 0.5%). Nî diffårånñås båtwåån thå grîups wårå îbsårvåd in mådiàn numbår îf IÑU îr hîspitàl dàós îr mådiàn dàós îf måñhàniñàl våntilàtiîn îr rånàl råplàñåmånt thåràpó. Ñîmmånt: Thå råsults îf thå NIÑÅ-SUGÀR triàl suggåst thàt intånsivå gluñîså ñîntrîl hàrms ñritiñàlló ill pàtiånts in tårms îf dåàth (numbår nåådåd tî hàrm, 38) ànd åpisîdås îf såvårå hópîglóñåmià. Às àn åditîriàlist nîtås, thå råsults dî nît suggåst thàt ñliniñiàns råvårt tî "någlåñtful" måàns îf gluñîså ñîntrîl, suñh às insulin sliding sñàlås, in ñritiñàlló ill pàtiånts. Inståàd, ñliniñiàns shîuld strivå fîr råàsînàblå ñîntrîl (i.å., gluñîså låvåls in thå mid-100s) in suñh pàtiånts. |
#28
|
||||
|
||||
Òîëüêî ÷òî îòñèäåëà íà çàñåäàíèÿõ GOLD, ãäå â åäèíîì èíòåðíàöèîíàëüíîì ïîðûâå ðàçáèðàëè âñå ãàéäû ïî ýòîé òåìå ïðèìåíèòåëüíî ê ÊÎÍÊÐÅÒÍÎÌÓ ïàöèíòó ( áûëè çàäàíû ïàðàìåòðû ìîäåëè ïàöèåíòà êàæäîé ãðóïïå è òðåáîâàëîñü îáúÿñíèòü , èñõîäÿ èõ ãàéäîâ è çàùèòèòü ëå÷åíèå ) - â ñóùåíîñòè ðå÷ü èäåò î ñòðàòèôèêàöèè ôàòàëüíûõ êàðäèàëüíûõ ðèñêîâ â çàâèñèìîñòè îò íåêèõ ïàðàìåòðîâ ïðåäøåñòâóþùåãî ãëèêåìè÷åñêîãî êîíòðîëÿ è âîçðàñòà - èíäèâèäóàëèçàöèÿ öåëåé ãëèêåìèè íà îñíâîàíèè èìåþùèõñÿ çíàíèé, ïîýòîìó âîçíèêàåò âñåãäà âîïðîñ - âîçðñò? ñòàæ äèàáåòà?
Ïîðîé ýòà ìîæåò ïðåâðàòèòüñÿ â ñóäå÷íîå ðàçáèðàòåëüñòâî ( ïðèìåíèòåëüíî ê íàøåé ñòðàíå), ïîåëèêó ÷åì âûøå ãëèêåìèÿ ïðè ïîñòóïëåíèè â ER ðår se, òåì âûøå ëåòàëüíîñòü - íî îòñþäà íå ñëåäóåò íåîáõîäèìîñòü ãèïîãëèêåìèé , à ïîääåðæàíèå ýóãëèêåìèè çàòðàòû è òðóä ñóòü ...
__________________
Ã.À. Ìåëüíè÷åíêî |
#29
|
|||
|
|||
Äà, à âîò ññûëêà âûøåóïîìÿíóòîå èññëåäîâàíèå â NEJM: http://content.nejm.org/cgi/content/short/360/13/1283
full text äîñòóïåí áåñïëàòíî. Òåì íå ìåíåå, áåëüãèéöû ïðîäîëæàþò áóäîðàæèòü îáùåñòâåííîñòü íîâûìè ÷ðåçâû÷àéíûìè äîêàçàòåëüñòâàìè. Î÷åðåäíîå èññëåäîâàíèå â The Lancet, íà ýòîò ðàç èññëåäîâàëàñü ïåäèàòðè÷åñêàÿ ïîïóëÿöèÿ: Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study Dirk Vlasselaers*, Ilse Milants*, Lars Desmet*, Pieter J Wouters, Ilse Vanhorebeek, Ingeborg van den Heuvel, Dieter Mesotten, Michael P Casaer, Geert Meyfroidt, Catherine Ingels, Jan Muller, Sophie Van Cromphaut, Miet Schetz, Greet Van den Berghe Lancet 2009; 373: 547–56 Summary Background Critically ill infants and children often develop hyperglycaemia, which is associated with adverse outcome; however, whether lowering blood glucose concentrations to age-adjusted normal fasting values improves outcome is unknown. We investigated the eff ect of targeting age-adjusted normoglycaemia with insulin infusion in critically ill infants and children on outcome. Methods In a prospective, randomised controlled study, we enrolled 700 critically ill patients, 317 infants (aged <1 year) and 383 children (aged ≥1 year), who were admitted to the paediatric intensive care unit (PICU) of the University Hospital of Leuven, Belgium. Patients were randomly assigned by blinded envelopes to target blood glucose concentrations of 2·8–4·4 mmol/L in infants and 3·9–5·6 mmol/L in children with insulin infusion throughout PICU stay (intensive group [n=349]), or to insulin infusion only to prevent blood glucose from exceeding 11·9 mmol/L (conventional group [n=351]). Patients and laboratory staff were blinded to treatment allocation. Primary endpoints were duration of PICU stay and infl ammation. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00214916. Findings Mean blood glucose concentrations were lower in the intensive group than in the conventional group (infants: 4·8 [SD 1·2] mmol/L vs 6·4 [1·2] mmol/L, p<0·0001; children: 5·3 [1·1] mmol/L vs 8·2 [3·3] mmol/L, p<0·0001). Hypoglycaemia (defi ned as blood glucose ≤2·2 mmol/L) occurred in 87 (25%) patients in the intensive group (p<0·0001) versus fi ve (1%) patients in the conventional group; hypoglycaemia defi ned as blood glucose less than 1·7 mmol/L arose in 17 (5%) patients versus three (1%) (p=0·001). Duration of PICU stay was shortest in the intensively treated group (5·51 days [95% CI 4·65–6·37] vs 6·15 days [5·25–7·05], p=0·017). The infl ammatory response was attenuated at day 5, as indicated by lower C-reactive protein in the intensive group compared with baseline (–9·75 mg/L [95% CI –19·93 to 0·43] vs 8·97 mg/L [–0·9 to 18·84], p=0·007). The number of patients with extended (>median) stay in PICU was 132 (38%) in the intensive group versus 165 (47%) in the conventional group (p=0·013). Nine (3%) patients died in the intensively treated group versus 20 (6%) in the conventional group (p=0·038). Interpretation Targeting of blood glucose concentrations to age-adjusted normal fasting concentrations improved short-term outcome of patients in PICU. The eff ect on long-term survival, morbidity, and neurocognitive development needs to be investigated. Çäåñü îáçîð-ïåðåâîä â ìîåì ñêðîìíîì èñïîëíåíèè íà ñàéòå medmir.com: http://www.medmir.com/content/view/2443/1/ Êîìó íóæåí fulltext îðèãèíàëüíîé ñòàòüè - îáðàùàéòåñü. |
#30
|
||||
|
||||
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
The mean time-weighted blood glucose level was lower in the intensive-control vs the standard-control groups (115 mg/dL vs 144 mg/dL, respectively). n the current study, intensive glucose control vs standard glucose control increased the risk for mortality in critically ill patients, and the 2 treatment strategies were similar in the outcomes of duration of mechanical ventilation, overall length of stay in the ICU, and the use of renal replacement therapy. |